ID   FR-M-101
AC   CVCL_C544
DR   cancercelllines; CVCL_C544
DR   Cosmic; 2163847
DR   ESTDAB; ESTDAB-160
DR   Wikidata; Q54835144
RX   PubMed=23851445;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Unspecified (PubMed=23851445).
ST   Source(s): ESTDAB=ESTDAB-160
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D3S1358: 14,18
ST   D5S818: 12
ST   D7S820: 9,11
ST   FGA: 22
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 16,19
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 13
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//